The Rise of AI Agents: Owkin and Sanofi Expand Collaboration to Rewrite the Drug Discovery Blueprint

drugscontrol.org·Jun 7

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Owkin and Sanofi are expanding their collaboration. The partnership aims to impact the drug discovery process, potentially altering its current approach. The collaboration is said to involve the use of ai agents.

Full coverage

Owkin, Sanofi expand AI collaboration to build drug development AI agents

MobiHealthNews·Jun 5

Owkin and Sanofi Expand Partnership to Develop AI Agents Through K Pro Collaboration

HLTH·Jun 8

Sanofi expands AI ambitions through new Owkin collaboration

The Pharma Letter·Jun 8

Owkin, Sanofi Expand AI Collaboration to Develop Drug Discovery Agents

Digital Health News·Jun 8

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi

Business Wire·Jun 5

Advancing Claude in healthcare and the life sciences

Anthropic·Jan 11

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

Business Wire·May 13

Sanofi’s AI Strategy: Analysis of Dominance in Biopharma

Klover.ai·Jul 22

View original report at drugscontrol.org ↗

Fetching the latest headlines…